Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBA-Itraconazole vs Sporanox for Onychomycosis
NCT00791219Phase 2Completed
- Sponsor
- Mayne Pharma
- Start
- Nov 2008
- Primary completion
- Jul 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SUBA itraconazole in onychomycosis (3 arms), sponsored by Mayne Pharma. Primary endpoints: Therapeutic Cure Rate at 24 weeks, Clinical Cure Rate at 24 weeks and 1 more. Started Nov 2008; status: completed.
02
Drugs
SUBA itraconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT00791219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791219.